NO813492L - Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol - Google Patents
Medikament basert paa 2-amino-6-trifluormetoksybenzotiazolInfo
- Publication number
- NO813492L NO813492L NO813492A NO813492A NO813492L NO 813492 L NO813492 L NO 813492L NO 813492 A NO813492 A NO 813492A NO 813492 A NO813492 A NO 813492A NO 813492 L NO813492 L NO 813492L
- Authority
- NO
- Norway
- Prior art keywords
- amino
- active substance
- trifluoromethoxy
- trifluorometoxybenzotiazole
- benzothiazole
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 230000001773 anti-convulsant effect Effects 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 230000000949 anxiolytic effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 239000002249 anxiolytic agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 5
- 241001279009 Strychnos toxifera Species 0.000 description 5
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
- 229960005453 strychnine Drugs 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 229940116357 potassium thiocyanate Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229950006967 zoxazolamine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8022218A FR2492258A1 (fr) | 1980-10-17 | 1980-10-17 | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO813492L true NO813492L (no) | 1982-04-19 |
Family
ID=9247013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO813492A NO813492L (no) | 1980-10-17 | 1981-10-16 | Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4370338A (cs) |
| EP (1) | EP0050551B1 (cs) |
| JP (1) | JPS5795910A (cs) |
| AR (1) | AR227069A1 (cs) |
| AU (1) | AU545437B2 (cs) |
| CA (1) | CA1166159A (cs) |
| DE (1) | DE3163230D1 (cs) |
| DK (1) | DK444281A (cs) |
| FR (1) | FR2492258A1 (cs) |
| GR (1) | GR75804B (cs) |
| HU (1) | HU184893B (cs) |
| IL (1) | IL63880A0 (cs) |
| MA (1) | MA19364A1 (cs) |
| NO (1) | NO813492L (cs) |
| PT (1) | PT73828B (cs) |
| ZA (1) | ZA817187B (cs) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826860A (en) * | 1987-03-16 | 1989-05-02 | Warner-Lambert Company | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents |
| FR2619713B1 (fr) * | 1987-08-25 | 1990-08-31 | Rhone Poulenc Sante | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression |
| FR2619712B1 (fr) * | 1987-08-25 | 1990-08-31 | Rhone Poulenc Sante | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie |
| US5236940A (en) * | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| FR2640624B1 (fr) * | 1988-12-15 | 1994-08-12 | Rhone Poulenc Sante | Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation |
| FR2649705B2 (fr) * | 1989-07-13 | 1994-09-23 | Rhone Poulenc Sante | Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation |
| EP0374041B1 (fr) * | 1988-12-15 | 1992-06-17 | Rhone-Poulenc Sante | Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation |
| FR2649703B1 (fr) * | 1989-07-13 | 1991-11-22 | Rhone Poulenc Sante | Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant |
| FR2640623B1 (fr) * | 1988-12-15 | 1991-03-22 | Rhone Poulenc Sante | Derives de la benzothiazoline, leurs procedes de preparation et les medicaments les contenant |
| FR2649701B2 (fr) * | 1988-12-15 | 1991-11-22 | Rhone Poulenc Sante | Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant |
| FR2640622B1 (fr) * | 1988-12-15 | 1991-03-22 | Rhone Poulenc Sante | Derives de l'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant |
| ES2052954T3 (es) * | 1988-12-15 | 1994-07-16 | Rhone Poulenc Sante | Derivados de imino-2-polifluoroalcoxi-6-benzotiazol, sus procedimientos de preparacion y los medicamentos que les contienen. |
| US5260297A (en) * | 1989-07-13 | 1993-11-09 | Rhone Poulenc Rorer, S.A. | 2-imino-3-alkylbenzothiazoline derivatives bearing a heterocyclic substituent on the alkyl group, their preparation and medicinal products containing them. |
| FR2649704B1 (fr) * | 1989-07-13 | 1991-11-22 | Rhone Poulenc Sante | Derives d'imino-2 ethyl-3 benzothiazoline, leurs procedes de preparation et les medicaments les contenant |
| FR2661910B1 (fr) * | 1990-05-11 | 1992-08-21 | Rhone Poulenc Sante | Derives d'imino-2 heterocyclylalkyl-3 benzothiazoline, leur preparation et les medicaments les contenant. |
| DK0409692T3 (da) * | 1989-07-13 | 1994-04-05 | Rhone Poulenc Sante | Derivater af 2-imino-3-heterocycloalkylbenzothiazolin, deres fremstilling og lægemidler med indhold deraf |
| FR2649702B1 (fr) * | 1989-07-13 | 1991-11-22 | Rhone Poulenc Sante | Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant |
| FR2662160B1 (fr) * | 1990-05-18 | 1992-07-24 | Rhone Poulenc Sante | Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant. |
| FR2662695A1 (fr) * | 1990-06-05 | 1991-12-06 | Rhone Poulenc Sante | Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant. |
| FR2662694A1 (fr) * | 1990-06-05 | 1991-12-06 | Rhone Poulenc Sante | Derives du benzoselenazole, leur preparation et les medicaments les contenant. |
| FR2663030A1 (fr) * | 1990-06-05 | 1991-12-13 | Rhone Poulenc Sante | Derives selenies de benzothiazoline leur preparation et les medicaments les contenant. |
| FR2663029B1 (fr) * | 1990-06-07 | 1992-07-31 | Rhone Poulenc Sante | Derives de benzothiazole, leur preparation et les medicaments les contenant. |
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| FR2699077B1 (fr) * | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| FR2700116B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants comme radioprotecteurs. |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| FR2726271B1 (fr) * | 1994-10-26 | 1996-12-06 | Rhone Poulenc Rorer Sa | Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole |
| FR2786101B1 (fr) | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
| FR2787028B1 (fr) | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| EP1142584A4 (en) * | 1999-01-12 | 2003-04-16 | Takeda Chemical Industries Ltd | COMPOSITIONS FOR THE TREATMENT OF COMMON URBANISM AND URINE CONTINENCE |
| EP1337271B1 (en) * | 2000-11-30 | 2004-11-03 | Pfizer Products Inc. | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
| AU2002215160A1 (en) | 2000-11-30 | 2002-06-11 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| KR20060011873A (ko) * | 2003-05-16 | 2006-02-03 | 화이자 프로덕츠 인코포레이티드 | 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물 |
| EP2343073A3 (en) | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| WO2005082372A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS |
| HUE050758T2 (hu) * | 2005-04-05 | 2021-01-28 | Univ Yale | Glutamátmoduláló szerek mentális rendellenességek kezelésére |
| CA2661448A1 (en) | 2005-08-25 | 2007-03-01 | Steven Michael Weiss | Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2643199A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| MX2008014320A (es) * | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2008030651A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080108827A1 (en) * | 2006-10-25 | 2008-05-08 | Padi Pratap R | Process for preparing riluzole |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
| US20090167322A1 (en) * | 2007-12-28 | 2009-07-02 | Erik Edmund Magnuson | Systems and method for classifying a substance |
| CN101983074A (zh) * | 2008-04-03 | 2011-03-02 | 弗·哈夫曼-拉罗切有限公司 | Peg化的igf-i变体在神经肌肉病治疗中的应用 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2284161A1 (en) | 2009-07-21 | 2011-02-16 | Edmond Pharma S.R.L. | Process for the preparation of riluzole |
| MX2017006454A (es) * | 2014-11-21 | 2018-03-23 | Biohaven Pharm Holding Co Ltd | Administracion sublingual de riluzol. |
| EP4039247B1 (en) | 2014-11-21 | 2025-11-05 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
| EP4119539A1 (en) | 2015-09-23 | 2023-01-18 | XWPharma Ltd. | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| EP3601235A4 (en) | 2017-03-30 | 2020-11-18 | XW Laboratories Inc. | BICYCLIC HETERARYL DERIVATIVES, PREPARATION AND ASSOCIATED USES |
| JP6996029B2 (ja) | 2018-09-30 | 2022-01-17 | エックスダブリューファルマ リミテッド | ニューロンヒスタミン受容体－３アンタゴニストとしての化合物およびその使用 |
| CN115244028A (zh) | 2019-12-20 | 2022-10-25 | 凯瑞康宁生物工程有限公司 | 4-缬氨酰氧基丁酸的合成方法 |
| CN115038432B (zh) | 2020-06-18 | 2023-12-26 | 凯瑞康宁生物工程（武汉）有限公司 | 水溶性活性药物成分的控制释放制粒 |
| KR20230008190A (ko) | 2020-06-18 | 2023-01-13 | 엑스더블유파마 리미티드 | 수용성 원료의약품의 약학적 과립화제 |
| CN116261451A (zh) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | γ-羟基丁酸衍生物的药物组合物和药物动力学 |
| CN115666527B (zh) | 2020-10-05 | 2025-03-07 | 凯瑞康宁生物工程有限公司 | γ-羟基丁酸衍生物的修饰释放组合物 |
| CN117098533A (zh) | 2021-03-19 | 2023-11-21 | 凯瑞康宁公司 | γ-羟基丁酸衍生物的组合释放型制剂的药物动力学 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879531A (en) * | 1972-07-17 | 1975-04-22 | Uniroyal Inc | 2-aminothiazoles compositions and methods for using them as psychotherapeutic agents |
| US3876653A (en) * | 1973-03-26 | 1975-04-08 | Kyowa Hakko Kogyo Kk | Benzothiazole derivatives |
-
1980
- 1980-10-17 FR FR8022218A patent/FR2492258A1/fr active Granted
-
1981
- 1981-09-18 IL IL63880A patent/IL63880A0/xx not_active IP Right Cessation
- 1981-10-01 GR GR66186A patent/GR75804B/el unknown
- 1981-10-05 US US06/308,695 patent/US4370338A/en not_active Expired - Lifetime
- 1981-10-07 DK DK444281A patent/DK444281A/da not_active Application Discontinuation
- 1981-10-09 DE DE8181401564T patent/DE3163230D1/de not_active Expired
- 1981-10-09 EP EP81401564A patent/EP0050551B1/fr not_active Expired
- 1981-10-15 PT PT73828A patent/PT73828B/pt unknown
- 1981-10-15 CA CA000387977A patent/CA1166159A/fr not_active Expired
- 1981-10-16 AU AU76545/81A patent/AU545437B2/en not_active Ceased
- 1981-10-16 HU HU812994A patent/HU184893B/hu not_active IP Right Cessation
- 1981-10-16 MA MA19508A patent/MA19364A1/fr unknown
- 1981-10-16 NO NO813492A patent/NO813492L/no unknown
- 1981-10-16 JP JP56165586A patent/JPS5795910A/ja active Granted
- 1981-10-16 ZA ZA817187A patent/ZA817187B/xx unknown
- 1981-10-19 AR AR287142A patent/AR227069A1/es active
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0148884B2 (cs) | 1989-10-20 |
| DE3163230D1 (en) | 1984-05-24 |
| JPS5795910A (en) | 1982-06-15 |
| PT73828B (fr) | 1983-01-17 |
| FR2492258B1 (cs) | 1982-11-26 |
| MA19364A1 (fr) | 1982-07-01 |
| AU545437B2 (en) | 1985-07-11 |
| EP0050551A1 (fr) | 1982-04-28 |
| PT73828A (fr) | 1981-11-01 |
| GR75804B (cs) | 1984-08-02 |
| CA1166159A (fr) | 1984-04-24 |
| US4370338A (en) | 1983-01-25 |
| AU7654581A (en) | 1982-04-22 |
| FR2492258A1 (fr) | 1982-04-23 |
| DK444281A (da) | 1982-04-18 |
| HU184893B (en) | 1984-10-29 |
| IL63880A0 (en) | 1981-12-31 |
| ZA817187B (en) | 1982-09-29 |
| EP0050551B1 (fr) | 1984-04-18 |
| AR227069A1 (es) | 1982-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO813492L (no) | Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol | |
| US4455298A (en) | Pharmaceutical preparations with gastro-protective action | |
| CZ295495A3 (en) | Pharmaceutical preparation and process for preparing thereof | |
| PL195736B1 (pl) | Sól wapniowa (1S,2R)-3-[[(4-aminofenylo)sulfonylo] (izobutylo) amino]-1-benzylo-2-(fosfonooksy)propylokarbaminianu (3S) tetrahydro-3-furanylu, sposóbjej wytwarzania i zastosowania oraz kompozycja farmaceutyczna | |
| US4226861A (en) | N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides | |
| MXPA01011071A (es) | Composicion farmaceutica en forma unitaria que contiene acido acetilsalicilico e hidrogenosulfato de clopidogrel. | |
| US2835702A (en) | Benzene 1, 3 disulfonamides possessing diuretic properties | |
| SK281193B6 (sk) | Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy | |
| JPS63130569A (ja) | カルボン酸アミド含有薬剤 | |
| KR100310041B1 (ko) | 틸리딘이수소오르토포스페이트,그제조방법및이를함유한의약제제 | |
| CA1202630A (en) | Imidazo¬1,2-a|pyrazines | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| BE882315A (fr) | Composes de 6-aryl pyrimidine, leur preparation et leur utilisation | |
| JPS6222785A (ja) | 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤 | |
| DK154136B (da) | Analogifremgangsmaade til fremstilling af 2-amino-3-benzoylphenylacetamider | |
| CN100422133C (zh) | 2-（α-羟基戊基）苯甲酸盐及其制法和用途 | |
| EP0123520B1 (en) | Process for preparing base salts of piroxicam deposited on a pharmaceutically-acceptable carrier | |
| US2931814A (en) | 4-alkylpyrazoles | |
| RU2090555C1 (ru) | Производные мочевины, способ получения производных мочевины, фармацевтическая композиция, обладающая ингибирующей активностью в отношении coa : холестерин-ацилтрансферазы (асат) | |
| RU2008015C1 (ru) | Способ получения витаминного средства "витапектин" | |
| US4001424A (en) | 1-Oxo-1H-naphtho [2,1-b] pyran derivatives for treating depression | |
| GB2154233A (en) | Aluminium salts of arylalkanoic acids and pharmaceutical compositions containing them | |
| KR0156926B1 (ko) | N-벤질-n-{[[1s, 5s)-6,6-디메틸비시클로-[3.1.1]헵트-2-일)-에톡시-에틸}-모르폴리늄염 함유 위보호용 약제 | |
| US3787440A (en) | 3-sulfamyl-4-chlorobenzoic acid derivatives | |
| US3743736A (en) | Method of killing helminths in warmblooded animals with 1,1,3-trisubstituted thioureas and compositions thereof |